

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	Cyclin dependent kinase (CDK)	<p>Studies in mice identified a pyrazoloquinazoline-based CDK inhibitor that could help treat cancer. In a mouse model of human ovarian cancer, the inhibitor reduced tumor growth by up to 75% compared with vehicle control (<math>p &lt; 0.0001</math>). Next steps could include characterizing the pharmacological profile of the pyrazoloquinazoline-based multi-CDK inhibitor.</p> <p>At least 10 companies have CDK inhibitors in Phase II or earlier to treat various cancers.</p> <p><b>SciBX 3(9); doi:10.1038/scibx.2010.272</b>  <b>Published online March 4, 2010</b></p>	Patent and licensing status unavailable	<p>Traquandi, G. <i>et al. J. Med. Chem.</i>; published online Feb. 8, 2010; doi:10.1021/jm901710h</p> <p><b>Contact:</b> Gabriella Traquandi, Nerviano Medical Sciences S.r.l., Nerviano, Italy            e-mail: <a href="mailto:gabriella.traquandi@nervianoms.com">gabriella.traquandi@nervianoms.com</a></p>